Metrizamide--CSF contrast medium. Analysis of clinical application in 215 patients.
Two-hundred-fifteen patients were evaluated with metrizamide, a new water-soluble contrast agent for use in the subarachnoid spaces. Side effects were reported in 67% of these; 39% were moderate or severe. Cervical injections monitored by fluoroscopy provide the most precise positioning of the medium. The benefits of metrizamide use outweigh its risk.
D002555:Cerebrospinal Fluid; D003287:Contrast Media; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007463:Iodobenzoates; D008793:Metrizamide / Q000009:adverse effects; D009192:Myelography / Q000379:methods*; D009325:Nausea / Q000139:chemically induced; D012640:Seizures / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D003287:Contrast Media; D007463:Iodobenzoates; D008793:Metrizamide